The Novel SSTR3 Full Agonist ITF2984 Shows Antitumor Properties against Pancreatic Neuroendocrine Tumors.

Saved in:
Bibliographic Details
Title: The Novel SSTR3 Full Agonist ITF2984 Shows Antitumor Properties against Pancreatic Neuroendocrine Tumors.
Authors: Bistika M; Department of Biology and Biotechnology 'L. Spallanzani', University of Pavia, Pavia, Italy., Marangelo A; Institute for Diabetes and Cancer, Helmholtz Zentrum München, Neuherberg, Germany.; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany., Ascione F; Department of Biology and Biotechnology 'L. Spallanzani', University of Pavia, Pavia, Italy., Valentini N; Department of Biology and Biotechnology 'L. Spallanzani', University of Pavia, Pavia, Italy., Fedeli F; Department of Biology and Biotechnology 'L. Spallanzani', University of Pavia, Pavia, Italy., Schrader J; Department of Medicine, Klinikum Nordfriesland, Husum, Germany., Modena D; Preclinical R&D, Italfarmaco Group, Milan, Italy., Steinkühler C; Preclinical R&D, Italfarmaco Group, Milan, Italy., Pellegata NS; Department of Biology and Biotechnology 'L. Spallanzani', University of Pavia, Pavia, Italy.; Institute for Diabetes and Cancer, Helmholtz Zentrum München, Neuherberg, Germany.; Joint Heidelberg-IDC Translational Diabetes Program, Heidelberg University Hospital, Heidelberg, Germany.
Source: Neuroendocrinology [Neuroendocrinology] 2025; Vol. 115 (5), pp. 446-459. Date of Electronic Publication: 2024 Dec 28.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Karger Country of Publication: Switzerland NLM ID: 0035665 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0194 (Electronic) Linking ISSN: 00283835 NLM ISO Abbreviation: Neuroendocrinology Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Be the first to leave a comment!
You must be logged in first